Building Stem Cell Treatments for Non-Healing Wounds

This review looks over progress in the use of stem cells treatments as a way to impact chronic inflammation and treat non-healing wounds:

A chronic wound develops when a wound fails to heal within an expected time frame and fails to achieve functional closure. There are many factors that impede healing, including co-morbid clinical conditions, aging, poor tissue perfusion, malnutrition, unrelieved pressure to the surface of the wound, immune suppression, malignancy, infection, obesity, and a number of medications. The usual patient with a nonhealing wound has a combination of several of the factors mentioned earlier, making any one therapeutic option unlikely to succeed.

One common thread with almost all nonhealing wounds is a persistent inflammatory state. Macrophages, known to mediate inflammation, influence healing in a positive way through increasing angiogenesis, decreasing bacterial loads, phagocytosing debris, and providing matrix deposition. If, however, a persistent inflammatory state develops in which the macrophages are dysregulated and become skewed toward a type I inflammatory phenotype, impeding progress toward wound repair and regeneration. Another potential explanation for the nonhealing wound is the presence of intrinsically dysfunctional or senescent cells that are incapable of responding to normal biochemical signals.

A number of treatment modalities are currently used to accelerate wound healing. The use of stem cell therapy has been hypothesized as a potentially useful adjunct for nonhealing wounds. Specifically, mesenchymal stem cells (MSCs) have been shown to improve wound healing in several studies. Immune modulating properties of MSCs have made them attractive treatment options. MSCs may be more useful if they are preactivated with inflammatory cytokines such as tumor necrosis factor alpha or interferon gamma.



Fantastic to see you reporting on Mesenchymal Stem Cells (MSC). This is the old stand by therapy that has been in use for over 40 years in treating cancer patients, so the safety is well understood. While there is lots of excitement about embryonic and induced pluripotent stem cells, neither has made it to human trials yet.

Expanded high dose MSC therapy has already been found safe in published trials in over 2,000 human subjects.

The high dose MSC approach is now being trialed for MS at Cleveland Clinic and Tisch MS Center. Mayo Clinic just announced a similar trial for ALS. In addition to recovering from incurable diseases, patients are reporting anti aging effects, which has led to the first anti-aging trial proposal at Baylor College of Medicine

Keep up the great work!

Posted by: SammyJo Wilkinson at March 9th, 2014 2:47 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.